RxDoctor Payments Data

Brittany Schley, PA

Physician Assistant · Davenport, FLNPI 1740844604

Payments from drug & device makers

$2,414in general payments, 2019–2025

Across 71 payments — averaging $34.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$603
  • Pfizer$510
  • Medtronic$265
  • Teleflex LLC$202
  • Myriad Genetic Laboratories, Inc.$116
  • Procept Biorobotics Corporation$96
  • plus $622 from 16 others

What the payments were for

  • Food & beverage$1,72772%
  • Education$68728%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,414 in reported general payments places this provider in the 80th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$18,615
Medicare patients
141
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrelstarTriptorelin Pamoate29$140,778
MyrbetriqMirabegron37$33,315
GemtesaVibegron22$20,393
Estradiol63$4,865
Tamsulosin Hcl309$2,792
Oxybutynin Chloride ErOxybutynin Chloride73$2,387
NitrofurantoinNitrofurantoin Macrocrystal37$1,506
Finasteride129$1,367
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst55$898
Testosterone Cypionate36$830
Ciprofloxacin Hcl164$531
Alfuzosin Hcl ErAlfuzosin Hcl29$500
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip22$423
Cephalexin44$417
Oxybutynin Chloride17$391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Verity Pharmaceuticals Inc.Trelstar$79$140,77829 claims
Astellas Pharma US IncMyrbetriq$603$33,31537 claims
Sumitomo Pharma America, Inc.Gemtesa$77$20,39322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Davenport

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →